The world is one step closer to a potential solution for Nipah virus, a deadly disease with pandemic potential. The Oxford Vaccine Group has launched the first-ever Phase II trial of a Nipah virus vaccine in Bangladesh, a region where the virus causes recurrent outbreaks. This groundbreaking trial, conducted in partnership with the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), and funded by the Coalition for Epidemic Preparedness Innovations (CEPI), will assess the safety and immune response of the ChAdOx1 NipahB vaccine in a region where the virus causes recurrent outbreaks. The trial started earlier this month and will enrol 306 healthy participants aged 18 to 55. Nipah virus, a deadly disease from the same viral family as measles, is a research priority for the World Health Organization due to its pandemic potential. A vaccine is urgently needed as the disease can be fatal in up to 75% of cases. First identified after an outbreak in Malaysia, Nipah virus causes small outbreaks in Bangladesh almost every year and occasionally in India. Of the 750 cases recorded since 1998, there have been 415 deaths. This trial marks a significant step forward in the fight against Nipah virus, offering hope for a potential vaccine that could save lives and prevent future outbreaks.
